Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer

This publication has 17 references indexed in Scilit:

• A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer
  Chemotherapy, 2015
• The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study
  Supportive Care in Cancer, 2013
• Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer
  Cancer Chemotherapy and Pharmacology, 2012
• Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer
  Anti-Cancer Drugs, 2011
• Impact of Cancer on Health-Related Quality of Life of Older Americans
  JNCI: Journal of the National Cancer Institute, 2009
• Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
  Journal of Clinical Oncology, 2006
• Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)
  Journal of Clinical Oncology, 2006
• Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
  JNCI: Journal of the National Cancer Institute, 1999
• Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
  Anti-Cancer Drugs, 1996
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
  JNCI: Journal of the National Cancer Institute, 1993